Head-to-head comparison
| Property | Semaglutide | Exenatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Prescription | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~7 days | ~2.4 hours (Byetta); ~2 weeks apparent t½ for Bydureon due to slow release |
| Mol. Weight | 4,113.58 Da | 4,186.6 Da |
| Side Effects | Nausea (39%), Vomiting, Diarrhea | Nausea (most common, typically transient), Vomiting, Diarrhea |
Key differences
- Origin: Exenatide is a synthetic version of exendin-4, a peptide found in Gila monster saliva; semaglutide is a modified analog of human GLP-1.
- Dosing: Semaglutide is dosed once weekly (Ozempic/Wegovy); exenatide comes in twice-daily (Byetta, 5–10 mcg) and once-weekly (Bydureon, 2 mg) formulations.
- Weight loss: Semaglutide (2.4 mg) achieves 15–17% weight loss in STEP trials; exenatide produces approximately 2–4% weight loss in diabetes trials.
- HbA1c reduction: Semaglutide demonstrates superior HbA1c reduction compared to exenatide in clinical comparisons.
- Half-life: Semaglutide has a half-life of approximately 7 days; exenatide immediate-release has a half-life of about 2.4 hours; extended-release (Bydureon) has sustained release over 7 days.
- Approval history: Exenatide was FDA-approved in 2005 (first GLP-1 agonist); semaglutide in 2017. Exenatide has the longest GLP-1 safety track record.
- Antibody formation: Exenatide (being non-human-derived) has higher rates of anti-drug antibody formation than semaglutide (a human GLP-1 analog).
The verdict
Semaglutide is the superior GLP-1 agonist by modern standards, with dramatically greater weight loss, better glycemic control, and more convenient weekly dosing. Exenatide's historical significance as the first GLP-1 agonist is important, but clinically it has been largely superseded. Exenatide may still be used when semaglutide is unavailable or for specific patient populations, but it is no longer considered first-line GLP-1 therapy.
Frequently asked questions
By current clinical metrics, yes. Semaglutide produces substantially more weight loss (15–17% vs 2–4%), superior HbA1c reduction, and requires fewer injections (weekly vs twice daily for immediate-release). Exenatide has been largely superseded by newer GLP-1 agonists.
Yes, exenatide (Byetta) was the first GLP-1 receptor agonist approved by the FDA in 2005. It was derived from exendin-4, a peptide discovered in Gila monster venom. It pioneered the GLP-1 drug class that semaglutide and tirzepatide now dominate.
Researchers discovered that exendin-4, a peptide in Gila monster saliva, activates the human GLP-1 receptor with much greater resistance to DPP-4 degradation than native GLP-1. This made it a viable drug candidate. Semaglutide later achieved even better stability through chemical modification of human GLP-1 itself.
Switching should be done under physician guidance. The typical approach is to stop exenatide and start semaglutide at the initial dose (0.25 mg weekly for Ozempic). Both are GLP-1 agonists, so the transition is pharmacologically straightforward but requires dose titration.
Both share GLP-1 class side effects (nausea, vomiting). Exenatide has higher rates of injection site reactions (particularly the extended-release microsphere formulation) and higher rates of anti-drug antibody formation due to its non-human origin. Semaglutide's human GLP-1 backbone reduces immunogenicity.